|

Top 11 Celebrities Whose Lives Were Changed by Psychedelics | Mike Tyson, Seth Rogen, Sting & More



Follow us on Twitter:
@PsycSpotlight
@Psy_Invest
@psy_holy

Follow us on Instagram:
@psycspotlight
@thepsychedelicinvestor

To learn more about the emerging psychedelic industry, visit:

Psychedelic Spotlight

To read the article:

11 Celebrities Whose Lives Were Changed by Psychedelics

From Sir Paul McCartney to Joe Rogan, these celebrities all credit psychedelics with changing their lives.

Scientific studies reveal what many cultures have known for thousands of years—psychedelic medicines hold the potential to heal the mind, body, and soul, and promote lasting change.

After a half-century of stigmatization following the War on Drugs, psychedelics have found a respectable place in research, with therapies like psilocybin, MDMA, ketamine, and DMT showing promise in treating notoriously difficult-to-treat mental health conditions including anxiety, depression, post-traumatic stress disorder (PTSD), and opioid addiction.

As public perception of psychedelics shifts, more people have begun to share how psychedelic medicine changed their lives for the better, including many celebrities. Here are some of their experiences.

1. Paul McCartney
2. Miley Cyrus
3. Seth Rogen
4. Ben Lee
5. Sting
6. Daniel Carcillo
7. Lamar Odom
8. Chelsea Handler
9. Joe Rogan
10. Mike Tyson
11. Paul Simon
#psychedelics #MikeTyson #SethRogen

source

Similar Posts

  • Compass Pathways launching NEW Phase II Clinical Trial to Treat PTSD!!!

    Compass Pathways is launching a NEW Phase II clinical trial to treat PTSD!!!
    The trial will use Comp 360, the company’s synthetic, proprietary version of psilocybin, in conjunction with therapy. This is Compass’ second major trial using Comp 360. They also are using it to treat Treatment Resistant Depression.

    On October 3rd, 2021, Compass Pathways (Nasdaq: CMPS) announced the launch of a brand new psychedelic therapy clinical trial, using Psilocybin, the active ingredient in magic mushrooms, to treat PTSD.
    The Phase 2 clinical trial will use Comp 360, Compass Pathways’ proprietary, synthetic, cristalline Psilocybin. It will be paired with talk psychotherapy in 20 adults who suffered trauma as an adult, resulting in PTSD.
    While using psychedelics for mental health may seem controversial, when it comes to the science, psychedelics like psilocybin and MDMA, when paired with therapy have been shown to work.
    For example, recently MAPS completed a Phase III clinical trial using MDMA therapy to treat PTSD, which showed 67% of people improving so much they no longer qualified to be diagnosed as having PTSD (cured?). Another 21% of people improved significantly.

    This Compass Pathways trial is exciting, because once it is complete, we will be able to compare the results of their psilocybin trial to MAPS’ MDMA trial, to start to have an understanding of which psychedelic compound works better for treating PTSD.
    This news comes as we are waiting for the results of Compass Pathways’ Phase 2b Clinical Trial, testing treating Treatment-Resistant Depression with Comp 360, to be released before the end of the year.
    The results of the trial will be significant, as it will be the largest ever clinical trial studying psychedelics, with 216 patients. It will also be the most advanced clinical trial studying psilocybin, being in phase 2b.
    In sum, these are very exciting times to be watching Compass Pathways. Controversies surrounding their patents aside, Compass is one of the companies pushing the frontiers of psychedelic medicines, which is very exciting to watch.

    Do you think psilocybin assisted therapy could treat PTSD? Let us know in the comments.

    Enjoy the episode!
    Follow us on social media!
    Instagram: @thepsychedelicinvestor
    Facebook: @thepsychedelicinvestor

    Want to collaborate? Send us an email at:
    thepsychedelicinvestor@gmail.com

    Music from:
    www.bensound.com
    Video editing: @themyaholy

    DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.
    All of the information in this video is public information that James (The Psychedelic Investor) believes to be reliable but it is not guaranteed to be 100% accurate and as such should not be used as advice. Any opinions or thoughts from James (The Psychedelic Investor) are subject to change.

    #CompassPathways #Psychedelics #CMPS

  • How Clinical Trials Work and Who is WINNING the Race (FOR NOW) // MAPS, CMPS, MNMD & more

    Who’s winning the psychedelics race and how do clinical trials work? This topic has been requested a lot lately so we decided to give you a rundown on the clinical trials system and the psychedelic-inspired companies who are furthest advanced at the moment. Of course, for now, MAPS is leading the race. However, other public companies such as Compass Pathways (CMPS) and MindMed (MMED / MNMD) are not far behind, for now.

    Hopefully, this introductory video will help some new retail investors who are considering investing in biotech companies who do not te have an approved drug, to understand the importance that clinical trials need to play in their investing decisions.

    Timestamps:
    0:00 – Intro
    1:34 – What is the clinical trial system?
    2:15 – Preclinical
    3:00 – Phase 0
    3:32 – Phase I
    5:45 – Phase II
    8:26 – Phase III
    10:28 – Phase IV
    11:08 – Who’s winning the race?
    11:16 – MAPS ( non-for-profit entity): Has already completed a Phase III study on MDMA to treat PTSD
    12:02 – Compass Pathways (CMPS) has a Phase IIb trial to treat TRD with COMP360
    12:28 – MindMed (MMED / MNMD) has completed a Phase IIa LSD study to treat Anxiety and will begin phase IIb this year. MindMed also has other Phase II studies involving LSD & Ibogaine (18-MC)
    13:23 – Mydecine (MYCO) and CYBIN (CYBN) following suit

    Remember to Like, Subscribe, and SMASH that notifications bell to keep up to date on all the latest Psychedelic Stocks news!
    Follow us on social media! 🙌

    Instagram: @psychedelicinvestor
    Email: thepsychedelicinvestor@gmail.com
    Facebook: @thepsychedelicinvestor
    editing by: @themyaholy
    Music: www.bensound.com
    https://benzinga.grsm.io/jameshallifax1834
    https://benzinga.grsm.io/thepsychedelicinvestor

    DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.

    All of the information in this video is public information that James (The Psychedelic Investor) believes to be reliable but it is not guaranteed to be 100% accurate and as such should not be used as advice. Any opinions or thoughts from James (The Psychedelic Investor) are subject to change.

    #MindMed #Numi #CMPS